Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Non-Current Deferred Tax Liability: 2018-2025

Historic Non-Current Deferred Tax Liability for OptimizeRx (OPRX) over the last 8 years, with Q3 2025 value amounting to $4.5 million.

  • OptimizeRx's Non-Current Deferred Tax Liability rose 6559.73% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year increase of 6559.73%. This contributed to the annual value of $4.5 million for FY2024, which is 355.08% up from last year.
  • Per OptimizeRx's latest filing, its Non-Current Deferred Tax Liability stood at $4.5 million for Q3 2025, which was up 6559.73% from $3.5 million recorded in Q2 2025.
  • In the past 5 years, OptimizeRx's Non-Current Deferred Tax Liability registered a high of $4.5 million during Q4 2024, and its lowest value of $2.3 million during Q4 2022.
  • Over the past 5 years, OptimizeRx's median Non-Current Deferred Tax Liability value was $4.1 million (recorded in 2023), while the average stood at $3.7 million.
  • Its Non-Current Deferred Tax Liability has fluctuated over the past 5 years, first skyrocketed by 8613.73% in 2023, then plummeted by 2026.75% in 2025.
  • Over the past 5 years, OptimizeRx's Non-Current Deferred Tax Liability (Quarter) stood at $2.6 million in 2021, then fell by 11.07% to $2.3 million in 2022, then skyrocketed by 86.14% to $4.3 million in 2023, then increased by 3.55% to $4.5 million in 2024, then changed by 0.0% to $4.5 million in 2025.
  • Its last three reported values are $4.5 million in Q3 2025, $3.5 million for Q2 2025, and $3.8 million during Q1 2025.